Literature DB >> 9627663

Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up.

E O Gullingsrud1, W Krivit, C G Summers.   

Abstract

OBJECTIVE: The purpose of the study was to provide longer follow-up of ocular findings in patients with mucopolysaccharidoses (MPS) after bone marrow transplantation (BMT).
DESIGN: The study design was a retrospective 6-year cohort evaluation. PARTICIPANTS: Twenty-three patients with MPS (19 with MPS type I-H, 3 with MPS type III, 1 with MPS type VI) were studied. INTERVENTION: Bone marrow transplantation was performed. MAIN OUTCOME MEASURES: The following outcome measures were considered: vision, slit-lamp biomicroscopic and funduscopic examinations, intraocular pressure, electroretinography (ERG), and retinoscopy.
RESULTS: Thirteen (81%) of 16 patients showed ERG improvement in the first year. However, all patients showed slowly progressive decline of the ERG over longer follow-up. Other ocular findings included optic atrophy (n = 7 patients), disc edema (n = 6 patients), strabismus (n = 6 patients), nystagmus (n = 6 patients), cataract (n = 3 eyes), keratoconjunctivitis sicca (n = 4 eyes), ocular hypertension (n = 2 eyes), and glaucoma (n = 2 eyes).
CONCLUSIONS: The MPS are rare and heterogeneous disorders characterized by progressive retinal degeneration and blindness. Ocular abnormalities can occur as a result of the disease or as a consequence of BMT. Successful BMT has been shown to improve systemic health, but this may not reflect continuing ocular status and retinal function. Despite early improvement in ERG function, longer follow-up suggests progressive retinal decline.

Entities:  

Mesh:

Year:  1998        PMID: 9627663     DOI: 10.1016/S0161-6420(98)96014-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

1.  Cardiac Ultrasound Findings in Infants with Severe (Hurler Phenotype) Untreated Mucopolysaccharidosis (MPS) Type I.

Authors:  L Schroeder; P Orchard; C B Whitley; J M Berry; J Tolar; W Miller; E A Braunlin
Journal:  JIMD Rep       Date:  2013-02-12

Review 2.  Hurdles in treating Hurler disease: potential routes to achieve a "real" cure.

Authors:  Brigitte T A van den Broek; Jaap van Doorn; Charlotte V Hegeman; Stefan Nierkens; Caroline A Lindemans; Nanda Verhoeven-Duif; Jaap Jan Boelens; Peter M van Hasselt
Journal:  Blood Adv       Date:  2020-06-23

3.  Anterior segment OCT imaging in mucopolysaccharidoses type I, II, and VI.

Authors:  T Y Ahmed; A M J Turnbull; N F Attridge; S Biswas; I C Lloyd; L Au; J L Ashworth
Journal:  Eye (Lond)       Date:  2014-01-03       Impact factor: 3.775

4.  A novel explanation of corneal clouding in a bone marrow transplant-treated patient with Hurler syndrome.

Authors:  Ching Yuan; Erick D Bothun; David R Hardten; Jakub Tolar; Linda K McLoon
Journal:  Exp Eye Res       Date:  2016-05-26       Impact factor: 3.467

5.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

6.  Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?

Authors:  Susanne Pitz; Olufunmilola Ogun; Laila Arash; Elke Miebach; Michael Beck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-22       Impact factor: 3.117

Review 7.  Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses.

Authors:  Carlton R Fenzl; Kyla Teramoto; Majid Moshirfar
Journal:  Clin Ophthalmol       Date:  2015-09-07

8.  AAV Gene Therapy for MPS1-associated Corneal Blindness.

Authors:  Melisa Vance; Telmo Llanga; Will Bennett; Kenton Woodard; Giridhar Murlidharan; Neil Chungfat; Aravind Asokan; Brian Gilger; Joanne Kurtzberg; R Jude Samulski; Matthew L Hirsch
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

9.  Negative ERGs in mucopolysaccharidoses (MPS) Hurler-Scheie (I-H/S) and Hurler (I-H)-syndromes.

Authors:  D Tzetzi; R Hamilton; P H Robinson; G N Dutton
Journal:  Doc Ophthalmol       Date:  2007-02-16       Impact factor: 1.854

Review 10.  Ophthalmological Findings in Mucopolysaccharidoses.

Authors:  Shizuka Tomatsu; Susanne Pitz; Ulrike Hampel
Journal:  J Clin Med       Date:  2019-09-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.